S. Courtney

发表

Steroidal Mineralocorticoid Receptor Antagonists: Synthesis and Biology

M. Brewer, C. Yarnold, A. Leonardi, 2017 .

Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.

J. Wityak, A. Beresford, L. Mrzljak, 2015, Journal of medicinal chemistry.

Allosteric Inhibition of the Neuropeptidase Neurolysin*

Paul N. Mortenson, J. Lange, C. Kruse, 2014, The Journal of Biological Chemistry.

Chiral Resolution and Pharmacological Characterization of the Enantiomers of the Hsp90 Inhibitor 2‐Amino‐7‐[4‐fluoro‐2‐(3‐pyridyl)phenyl]‐4‐methyl‐7,8‐dihydro‐6H‐quinazolin‐5‐one Oxime

S. Minucci, C. Mercurio, R. Amici, 2014, ChemMedChem.

Modulation of the Kynurenine Pathway for the Potential Treatment of Neurodegenerative Diseases

A. Scheel, S. Courtney, 2010 .

Phthalazinone pyrazoles as potent, selective, and orally bioavailable inhibitors of Aurora-A kinase.

R. Engh, G. Georges, Petra Rueger, 2011, Journal of medicinal chemistry.

Glyco- and peptidomimetics from three-component Joullié-Ugi coupling show selective antiviral activity.

Benjamin G Davis, Christopher J Schofield, B. G. Davis, 2005, Journal of the American Chemical Society.

2,3-Dihydro-1,3-dioxo-1H-isoindole-5-carboxylic acid derivatives: a novel class of small molecule heparanase inhibitors.

J. Bennett, D. Porter, D. Scopes, 2004, Bioorganic & medicinal chemistry letters.

A new convenient procedure for the synthesis of pyrrolo[2,1-c][l,4]benzodiazepines

D. Thurston, S. Courtney, 1993 .

Exploiting differences in caspase-2 and -3 S₂ subsites for selectivity: structure-based design, solid-phase synthesis and in vitro activity of novel substrate-based caspase-2 inhibitors.

C. Dominguez, F. Eustache, F. Krieger, 2011, Bioorganic & medicinal chemistry.

Fragment‐based Identification of Hsp90 Inhibitors

Mark Whittaker, Thomas Hesterkamp, Dirk Winkler, 2009, ChemMedChem.

Targeting deubiquitinase activity with a novel small-molecule inhibitor as therapy for B-cell malignancies.

A. Jakubowiak, S. Malek, N. Donato, 2015, Blood.

A Profiling Platform for the Characterization of Transglutaminase 2 (TG2) Inhibitors

J. Wityak, C. Dominguez, R. Pacifici, 2010, Journal of biomolecular screening.

Discovery of a Novel Hsp90 Inhibitor by Fragment Linking

Mark Whittaker, Thomas Hesterkamp, Oliver Barker, 2010, ChemMedChem.

Discovery and structure-activity relationship of potent and selective covalent inhibitors of transglutaminase 2 for Huntington's disease.

Andreas Ebneth, Sabine Schaertl, Andreas Scheel, 2012, Journal of medicinal chemistry.

Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor.

J. Bennett, D. Scopes, C. Stubberfield, 2005, Bioorganic & medicinal chemistry letters.

SAR Development of Lysine-Based Irreversible Inhibitors of Transglutaminase 2 for Huntington's Disease.

J. Wityak, C. Dominguez, M. Beconi, 2012, ACS medicinal chemistry letters.

Irreversible 4-Aminopiperidine Transglutaminase 2 Inhibitors for Huntington's Disease.

J. Wityak, C. Dominguez, O. Ichihara, 2012, ACS medicinal chemistry letters.